ArticleClinical ophthalmology (Auckland, N.Z.)2025
The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars Plana Vitrectomy Surgery.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes. Methods: One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed. Results: Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered. Conclusion: Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.